

**NOTICE**

**URGENT - Voluntary market withdrawal – January 21, 2022  
octagam<sup>®</sup> [Immune Globulin Intravenous (human)] 10% Liquid Preparation]  
Lot Number K139A8561**

Dear Healthcare Professional:

On January 21, 2022 in the interest of patient safety, Octapharma USA, Inc. initiated a voluntary market withdrawal of one lot of octagam<sup>®</sup> [Immune Globulin Intravenous (human)] 10% Liquid Preparation]. This was performed as a result of an increased number of reports of hypersensitivity events. Although most cases resolved without serious injury there was a case that required hospitalization.

**Effective immediately, Octapharma USA Inc. is initiating a voluntary market withdrawal of octagam<sup>®</sup> 10% [Immune Globulin Intravenous (human)] 10% Liquid Preparation] that is labeled with lot number K139A8561. Octapharma has determined, through consultation with the public health authorities at FDA, the most prudent course of action is to suspend further administration of this Octagam<sup>®</sup> from this production lot.**

Hypersensitivity reactions, including urticaria, wheezing, and anaphylactoid-type responses, have been observed with all intravenous immune globulin products through published literature and post-marketing surveillance. The potential occurrence of these adverse events are listed in all manufacturer package inserts. A copy of the Octagam<sup>®</sup> package insert is enclosed.

Distributors that received this particular lot of octagam<sup>®</sup> 10% directly from Octapharma are asked to immediately quarantine this lot and contact Octapharma's Customer Service Department at (800) 766-4860 for instructions regarding the return of the withdrawn product. If you have further distributed this lot of octagam<sup>®</sup> 10% to health care providers or facilities, please contact them to quarantine these lots and instruct them to return the affected product to you. Please also ask these customers to complete the attached Information Form that is included with this letter and fax a copy of that Information Form to Octapharma's Customer Service Department at (201) 604-1141.

We appreciate your immediate attention to this voluntary market withdrawal and sincerely regret any difficulty caused by this action. Most importantly, this voluntary market withdrawal is being performed in the interest of patient safety.

Octapharma USA, Inc.  
117 West Century Road  
Paramus, NJ 07652  
USA

---

phone: (201) 604-1130  
Fax: (201) 604-1131  
[www.octapharma.com/usa](http://www.octapharma.com/usa)

---

Sincerely,

s/n

Dipen Patel, M.S.  
Head of US Drug Safety Unit,  
Scientific and Medical Affairs  
Octapharma USA, Inc.  
117 West Century Rd.  
Paramus, NJ 07652  
Dipen.Patel@octapharma.com  
Phone: (201) 604-1137  
Fax: (201) 604-1141

Customer Service Department  
uscustomerservice@octapharma.com  
Phone: (866) 766-4860  
Fax: (201) 604-1141

Octapharma USA, Inc.  
117 West Century Road  
Paramus, NJ 07652  
USA

---

phone: (201) 604-1130  
Fax: (201) 604-1131  
[www.octapharma.com/usa](http://www.octapharma.com/usa)

---